All In Biotech

Drug Trial Radar · NCT05126303

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

177

Actual

Start

Mar 31, 2022

Primary completion

Apr 15, 2023

Study completion Jul 12, 2023

Sponsor

Lead sponsor
Guard Therapeutics ABIndustry
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates RMC-035 compared to placebo for the prevention of acute kidney injury (AKI) in subjects who are at high risk for AKI following cardiac surgery. Half of the subjects will receive RMC-035 and the other half will receive placebo.

Conditions

  • Acute Kidney Injury

Interventions

  • RMC-035Drug

    Concentrate for Solution for Infusion

  • PlaceboDrug

    Concentrate for Solution for Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Developing AKI, as Defined Per Kidney Disease Improving Global Outcomes (KDIGO) CriteriaTime frame: 72 hours

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • Indiana Ohio Heart

    Fort Wayne, Indiana

  • Bryan Heart

    Lincoln, Nebraska

  • Rochester Regional Health - Rochester General Hospital

    Rochester, New York

  • Duke University Hospital

    Durham, North Carolina

  • Baylor Scott and White Research Institute - Dallas

    Dallas, Texas

  • University of Virginia (UVA) Health - University Hospital

    Charlottesville, Virginia

  • University of Wisconsin

    Madison, Wisconsin

  • Aurora Health Care - Aurora St. Luke's Medical Center

    Milwaukee, Wisconsin

  • Hamilton Health Sciences

    Hamilton, Canada

  • CHUM

    Montreal, Canada

  • MUHC - Royal Victoria Hospital

    Montreal, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Québec

    Québec, Canada

  • St. John Regional Hospital

    Saint John, Canada

  • Saint Michael's Hospital

    Toronto, Canada

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia

  • University Hospital Motol - Charles University Prague

    Prague, Czechia

  • Herz- und Diabeteszentrum Nordrhein-Westfalen (NRW)

    Bad Oeynhausen, Germany

  • Universitätsklinikum Köln

    Cologne, Germany

  • Herzzentrum Dresden GmbH

    Dresden, Germany

  • Westdeutsches Herzzentrum Essen

    Essen, Germany

  • Universitätsklinikum Giessen und Marburg - Standort Giessen

    Giessen, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

  • Deutsches Herzzentrum München

    München, Germany

  • Münster University Hospital

    Münster, Germany

  • Hospital Sant Pau

    Barcelona, Spain

  • Reina Sofia University Hospital

    Córdoba, Spain

  • Hospital de La Princesa

    Madrid, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, Spain

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.